A first-in-human study of CAL101, a monoclonal antibody targeting S100A4.
AIMS S100A4 is a damage-associated molecular pattern protein that amplifies pro-inflammatory and pro-fibrotic signalling. CAL101 is a first-in-class humanized monoclonal antibody that neutralizes S100A4. This first-in-human study evaluated safety, pharmacokinetics (PK), immunogenicity and exploratory pharmacodynamics (...